InVivo Therapeutics Holdings Corp. (NVIV) today announced that
James Guest, M.D., Ph.D., has joined its Scientific Advisory Board. Dr.
Guest is currently a Professor of Neurological Surgery at the Miller
School of Medicine and the Miami Project to Cure Paralysis in Miami, FL.
Dr. Guest’s extensive contributions to the field of spinal cord injury,
both in terms of medical practice and research, span over two decades.
He’s held numerous hospital appointments such as attending neurosurgeon
at the Barrow Neurological Institute, West Palm Beach VA Medical Center,
the University of Miami Hospital, and Chief of Spinal Neurosurgery at
Miami Veteran’s Medical Center. He’s given more than 25 invited lectures
domestically and internationally and has authored over 75 peer-reviewed
publications, including articles, book chapters, and abstracts in the
areas of cellular therapy for spinal cord injury, biology of neuroglia,
and mechanisms of secondary injury. Dr. Guest has been active in
research design for human clinical trials, participating as a Principal
Investigator for the North American Clinical Trials Network (NACTN) for
the Treatment of Spinal Cord Injury.
Dr. Guest earned a Bachelor of Arts in Economics and Political Science,
a Bachelor of Science in Chemistry and Biology, and a Medical Degree
from the University of Alberta, Edmonton in Canada. He also earned a
Ph.D. from the University of Miami, Department of Neuroscience in Miami,
FL. His thesis was titled “The potential for human Schwann cell grafts
to influence spinal cord regeneration in the nude rat.” Dr. Guest
completed his residency in the Division of Neurosurgery at the
University of British Columbia in Vancouver, Canada and a fellowship in
Spinal Surgery at the Barrow Neurologic Institute in Phoenix, Arizona.
“Dr. Guest is widely regarded and respected for his scientific and
medical contributions to the field of spinal cord injury and I am very
pleased to welcome him to our Scientific Advisory Board,” said Mark
Perrin, InVivo’s Chief Executive Officer and Chairman.
“I am honored to join this Scientific Advisory Board. InVivo is
advancing a new direction in spinal cord injury therapy. It is bold, but
may open the door for new approaches in an area that remains without
effective treatment,” said Dr. Guest.
Dr. Guest joins a world renowned group of research and development
experts that include:
-
Robert Langer, Sc.D., David H. Koch Institute Professor at the
Massachusetts Institute of Technology (MIT), holds the largest number
of medical patents with >1,050 patents issued and pending worldwide.
Being an Institute Professor is the highest honor that can be awarded
to a faculty member at MIT.
-
Sir Richard Roberts, Ph.D. was awarded the 1993 Nobel Prize in
Medicine and Physiology for his contributions to genomics and the
discovery of split genes.
-
V. Reggie Edgerton, Ph.D., Distinguished Professor and Vice Chairman
of the Integrative Biology and Physiology at the University of
California, Los Angeles, authored the recent (April 2014) Brain
article showing recovery of motor function in paraplegic patients
after electrostimulation.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage
biomaterials and biotechnology company with a focus on treatment of
spinal cord injuries. The company was founded in 2005 with proprietary
technology co-invented by Robert Langer, Sc.D., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
then was at Boston Children’s Hospital and who now is affiliated with
Massachusetts General Hospital. In 2011, the company earned the David S.
Apple Award from the American Spinal Injury Association for its
outstanding contribution to spinal cord injury medicine. In 2015, the
company’s investigational Neuro-Spinal Scaffold received the 2015
Becker’s Healthcare Spine Device Award. The publicly-traded company is
headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150615005662/en/
Copyright Business Wire 2015